Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway.
Tirzepatide通過抑制TLR4/NF-kB/NLRP3途徑,減輕脂多糖誘導的左心室重塑和功能障礙。
Int Immunopharmacol 2023-07-06
Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats.
Tirzepatide透過調節糖尿病大鼠中異常胰島素抵抗和炎症反應,改善空間學習和記憶障礙。
Front Pharmacol 2023-09-15
The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice.
雙胰素增生素共激動劑 tirzepatide 在小鼠模型實驗中增加胰島素分泌和葡萄糖效能。
Peptides 2024-01-08
Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model.
Liraglutide與pramlintide在保護高脂飲食-腺苷脫氧核糖核酸大鼠模型中的認知功能損傷方面的比較:對PI3K/AKT/GSK-3β/TTBK1途徑的影響和減少Tau過度磷酸化。
Pflugers Arch 2024-05-07
The potential role of Tirzepatide as adjuvant therapy in countering colistin-induced nephro and neurotoxicity in rats via modulation of PI3K/p-Akt/GSK3-β/NF-kB p65 hub, shielding against oxidative and endoplasmic reticulum stress, and activation of p-CREB/BDNF/TrkB cascade.
Tirzepatide作為輔助治療對抗大腸桿菌素誘導的腎臟和神經毒性在大鼠中的潛在作用:透過調節PI3K/p-Akt/GSK3-β/NF-kB p65中樞,保護免受氧化和內質網壓力,並激活p-CREB/BDNF/TrkB級聯。
Int Immunopharmacol 2024-05-24
Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
Tirzepatide透過長效活化腸骨肽激素受體,調節脂肪細胞營養代謝的調控。
Cell Metab 2024-06-15
The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.
雙重葡萄糖依賴性胰島素促進多肽/類胰高血糖素肽-1 受體激動劑 tirzepatide 對於結合肥胖、2型糖尿病及更年期的小鼠體重變化、脂聯素、胰島素及瘦素水平的影響。
Diabetes Obes Metab 2024-08-08
The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice.
GLP-1 藥物 semaglutide 和 tirzepatide 不會改變 5XFAD 和 APP/PS1 小鼠的疾病相關病理、行為或認知功能。
Mol Metab 2024-08-31